SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-088994
Filing Date
2022-08-11
Accepted
2022-08-11 07:05:53
Documents
14
Period of Report
2022-08-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2223105d1_8k.htm   iXBRL 8-K 28383
2 EXHIBIT 99.1 tm2223105d1_ex99-1.htm EX-99.1 199419
6 GRAPHIC tm2223105d1_ex99-1img01.jpg GRAPHIC 5233
  Complete submission text file 0001104659-22-088994.txt   430710

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvlp-20220810.xsd EX-101.SCH 3033
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvlp-20220810_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvlp-20220810_pre.xml EX-101.PRE 22595
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2223105d1_8k_htm.xml XML 3602
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Filer) CIK: 0001739426 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38709 | Film No.: 221153635
SIC: 2834 Pharmaceutical Preparations